High Grade B-Cell Lymphoma

hematologic malignancy

Identifier: CI-CAN-00007803
Entity page: /cancer/high-grade-b-cell-lymphoma ↗
Edges: 209

Neighbours: 16 drugs10 trials
Drawn: 26 of 26 neighbours (cap 60); table lists every fetched edge

Accepted: cancer:<slug>, gene:<symbol>, variant:<slug>, drug:<slug>, trial:<NCT id>, or a bare CI id. Find slugs with search.

Most connectedLung Non-Small Cell Carcinoma 3,147 Malignant Colorectal Neoplasm 1,866 ABL1 298 EGFR 276 Imatinib 450 Dasatinib 321

Neighbourhood

Radial view

Focus at the centre; neighbours grouped by entity type. Click a node to re-centre the graph on it; ↗ opens the entity page. Hover a spoke for relationship, evidence level, cancer context and source.

Edges

Every edge, grouped by relationship

Source-native edges first (aggregated per neighbour, direction, evidence level and source), then derived registry links. Up to 15 per relationship (10 trials); “show all” raises one group to 200.

Relationship	Neighbour	Direction	Evidence level	Cancer context	Support	Claim	Source	Expand
High Grade B-Cell Lymphoma approved for …APPROVED_FOR4 of 4
← approved for	Loncastuximab Tesirineadc	supports	FDA ORIG	High Grade B-Cell Lymphoma	1	Regulatory	openfda	graph →
← approved for	Polatuzumab Vedotinadc	supports	FDA ORIG

High Grade B-Cell Lymphoma investigated in trials for …INVESTIGATED_IN_TRIALSderived15 of 63show all (up to 200)
→ investigated in trials for	Cyclophosphamidesmall molecule 43 trials (25 active) · roll-up of the cancer and its descendants	—	—	High Grade B-Cell Lymphoma	43	Observed	clinicaltrials	graph →
→ investigated in trials for	Rituximabmonoclonal antibody 37 trials (21 active) · roll-up of the cancer and its descendants	—	—	High Grade B-Cell Lymphoma	37	Observed	clinicaltrials	graph →
→ investigated in trials for	Doxorubicinsmall molecule 22 trials (14 active) · roll-up of the cancer and its descendants	—	—	High Grade B-Cell Lymphoma	22	Observed	clinicaltrials	graph →
→ investigated in trials for	Prednisonesmall molecule 21 trials (15 active) · roll-up of the cancer and its descendants	—	—	High Grade B-Cell Lymphoma	21	Observed	clinicaltrials	graph →
→ investigated in trials for	Etoposidesmall molecule 19 trials (12 active) · roll-up of the cancer and its descendants	—	—	High Grade B-Cell Lymphoma	19	Observed	clinicaltrials	graph →
→ investigated in trials for	Fludarabinesmall molecule 18 trials (9 active) · roll-up of the cancer and its descendants	—	—	High Grade B-Cell Lymphoma	18	Observed	clinicaltrials	graph →
→ investigated in trials for	Vincristinesmall molecule 18 trials (10 active) · roll-up of the cancer and its descendants	—	—	High Grade B-Cell Lymphoma	18	Observed	clinicaltrials	graph →
→ investigated in trials for	Epcoritamabmonoclonal antibody 12 trials (10 active) · roll-up of the cancer and its descendants	—	—	High Grade B-Cell Lymphoma	12	Observed	clinicaltrials	graph →
→ investigated in trials for	Axicabtagene Ciloleucelgene_therapy 9 trials (4 active) · roll-up of the cancer and its descendants	—	—	High Grade B-Cell Lymphoma	9	Observed	clinicaltrials	graph →
→ investigated in trials for	Lenalidomidesmall molecule 9 trials (6 active) · roll-up of the cancer and its descendants	—	—	High Grade B-Cell Lymphoma	9	Observed	clinicaltrials	graph →
→ investigated in trials for	Polatuzumab Vedotinadc 8 trials (7 active) · roll-up of the cancer and its descendants	—	—	High Grade B-Cell Lymphoma	8	Observed	clinicaltrials	graph →
→ investigated in trials for	Cytarabinesmall molecule 7 trials (4 active) · roll-up of the cancer and its descendants	—	—	High Grade B-Cell Lymphoma	7	Observed	clinicaltrials	graph →
→ investigated in trials for	Dexamethasonesmall molecule 7 trials (4 active) · roll-up of the cancer and its descendants	—	—	High Grade B-Cell Lymphoma	7	Observed	clinicaltrials	graph →
→ investigated in trials for	Glofitamabmonoclonal antibody 7 trials (6 active) · roll-up of the cancer and its descendants	—	—	High Grade B-Cell Lymphoma	7	Observed	clinicaltrials	graph →
→ investigated in trials for	Gemcitabinesmall molecule 6 trials (4 active) · roll-up of the cancer and its descendants	—	—	High Grade B-Cell Lymphoma	6	Observed	clinicaltrials	graph →

High Grade B-Cell Lymphoma investigated in trials for …INVESTIGATED_IN_TRIALSderived15 of 63show all (up to 200)

→ investigated in trials for

Cyclophosphamidesmall molecule

43 trials (25 active) · roll-up of the cancer and its descendants

—

High Grade B-Cell Lymphoma

Observed

High Grade B-Cell Lymphoma studied in …STUDIED_INderived10 of 142show all (up to 200)
→ studied in	NCT04231877Phase 1 · active not recruiting Polatuzumab Vedotin and Combination Chemotherapy With or Without Glofitamab for the Treatment of Untreated Aggressive Large B-cell Lymphoma · condition mapped CURATED_BROADER · 142 trials mapped (91 active)	—	—	High Grade B-Cell Lymphoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT06649812Phase 2 · recruiting Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell Lymphoma · condition mapped CURATED_BROADER · 142 trials mapped (91 active)	—	—	High Grade B-Cell Lymphoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT03418038Phase 2 · recruiting Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia · condition mapped ONTOLOGY_EXACT · 142 trials mapped (91 active)	—	—	High Grade B-Cell Lymphoma with MYC and BCL2 or BCL6 Rearrangements	1	Observed	clinicaltrials	graph →
→ studied in	NCT05600686Phase 2 · active not recruiting Loncastuximab Tesirine and Rituximab Followed by DA-EPOCH-R for Treating Patients With High-Risk Diffuse Large B-cell Lymphoma · condition mapped ONTOLOGY_EXACT · 142 trials mapped (91 active)	—	—	High Grade B-Cell Lymphoma with MYC and BCL2 and/or BCL6 Rearrangements	1	Observed	clinicaltrials	graph →
→ studied in	NCT04594642Phase 1 · active not recruiting A Study of AZD0486 in Subjects With B-Cell Non-Hodgkin Lymphoma · condition mapped CURATED_BROADER · 142 trials mapped (91 active)	—	—	High Grade B-Cell Lymphoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT05025800Phase 1/Phase 2 · active not recruiting ALX148, Rituximab and Lenalidomide for the Treatment of Indolent and Aggressive B-cell Non-Hodgkin Lymphoma · condition mapped CURATED_BROADER · 142 trials mapped (91 active)	—	—	High Grade B-Cell Lymphoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT06830031Phase 1 · recruiting Clinical Study of C402-CD19-CAR Treatment in Subjects With Relapsed or Refractory B-cell Lymphoma · condition mapped CURATED_BROADER · 142 trials mapped (91 active)	—	—	High Grade B-Cell Lymphoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT07098364Phase 1/Phase 2 · suspended ST-067 in Combination With CD19-Directed CAR T-Cell Therapy (Liso-cel) in Relapsed/Refractory Large B-Cell Lymphoma · condition mapped CURATED_BROADER · 142 trials mapped (91 active)	—	—	High Grade B-Cell Lymphoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT07814001Phase 2 · not yet recruiting Epcoritamab Plus Lenalidomide in Relapsed/Refractory Large B-cell Lymphoma After Second-Line CAR T-cell Therapy · condition mapped CURATED_BROADER · 142 trials mapped (91 active)	—	—	High Grade B-Cell Lymphoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT03625037Phase 1/Phase 2 · active not recruiting First-in-Human (FIH) Trial in Patients With Relapsed, Progressive or Refractory B-Cell Lymphoma · condition mapped CURATED_BROADER · 142 trials mapped (91 active)	—	—	High Grade B-Cell Lymphoma	1	Observed	clinicaltrials	graph →

Radial view

Every edge, grouped by relationship

Strongest chains